Viatris (VTRS) Q2 2026 Earnings Call Transcript
Viatris (VTRS) reported Q2 2026 revenue of $3.8B, up 3.5% operationally, with adjusted EBITDA of $1.2B and adjusted EPS of $0.69. Management raised 2026 guidance for revenue ($14.55B-$14.95B), adjusted EBITDA ($4.3B-$4.5B) and adjusted EPS ($2.45-$2.59). It also cited Nashik supply disruptions and FDA approval for its Gwyn Lo patch.
How this was made
The 30-second read
Why it matters
Traders can update 2026 model assumptions using the raised guidance midpoints, incorporate the Nashik second-half revenue reduction range, and factor in new product catalysts (FDA approval for Gwyn Lo patch) plus portfolio cash generation (Tyrvaya rights sale, Biocon equity monetization).
Market read
Raised 2026 guidance and FDA approval are near-term positives, but the Nashik facility fire and FDA inspection create a quantified 2H revenue headwind that can dominate estimate revisions.
What to watch
The Tyrvaya divestiture drives GAAP loss via non-cash charges, so investors focused on GAAP may misread underlying cash earnings; also, the estradiol patch fulfillment rate (70% of orders) suggests demand is strong but supply ramp execution is critical.
Background
This is Viatris’ Q2 2026 earnings call transcript with segment performance, guidance updates, and specific operational and portfolio actions.
Ticker impact
Viatris raised 2026 revenue, adjusted EBITDA, and adjusted EPS guidance after Q2 results, while also flagging Nashik supply disruptions.
Likely choppy reaction: upside from raised guidance and FDA approval, tempered by the $100M to $150M second-half revenue hit.
The article provides multiple new decision-relevant datapoints (raised guidance midpoints, FDA approval, divestiture, Nashik disruption range). Net impact depends on how the market prices the supply hit versus the guidance uplift and new product ramp.
Market effects
Signals continued momentum in complex generics and Greater China e-commerce, but highlights manufacturing fragility risk that can affect generic supply chains.
Greater China strength (16% operational growth, 36% e-commerce growth) contrasts with emerging markets decline tied to ARV generic supply constraints.
FDA approval and product-right divestiture show ongoing portfolio reshaping, which can influence sentiment across large generic pharma peers.
Counterpoint
The raised guidance may be partially a timing effect, with the Nashik facility disruption range ($100M to $150M) potentially pressuring 2H margins and offsetting operational leverage.
Key entities
- companyViatris Inc.
Reported Q2 2026 results, raised full-year 2026 guidance, received FDA approval for a weekly transdermal contraceptive patch, and outlined supply disruption and pipeline timing risks.
- regulatorFDA
Approved Viatris’ weekly transdermal hormonal contraceptive patch in July 2026, enabling a later-2026 commercial launch.
- companyHarrow, Inc.
Agreed transaction for Viatris to sell global rights to Tyrvaya for $30 million upfront plus up to $70 million in milestones.
- companyBiocon Limited
Viatris completed monetization of its equity position for $380 million, totaling $780 million in proceeds.
